Toothache, back pain top list of 'avoidable' reasons to visit ED

Reducing the amount of avoidable emergency department (ED) visits could save healthcare organizations money while also improving patient health. A study in the International Journal for Quality in Health Care examined the types of avoidable ED visits to provide policymakers with data to help limit unnecessary ED visits.

The study used data from the National Hospital Ambulatory Medical Care Survey, covering avoidable ED visits from 2005 to 2011. Researchers examined 115,081 records of 424 million ED visits of patients seen in the ED and then discharged. ‘Avoidable’ visits were defined as those that did not require diagnostic or screening procedures and medications.

Results found 3.3 percent of ED visits were avoidable. The top five concerns for visiting the ED were toothaches, backpain, headache, symptoms related to psychosis and throat soreness. Additionally, alcohol abuse, dental disorder and depressive disorders were among the top ICD-9 discharges diagnoses. Alcohol and mood disorders accounted for 6.8 percent of avoidable visits, dental disorders accounted for 3.9 percent of diagnoses.

“A significant number of ‘avoidable’ ED visits were for mental health and dental conditions, which the ED is not fully equipped to treat,” concluded first author Renee Y. Hsia, of the Department of Emergency Medicine, University of California at San Francisco. “Our findings provide a better understanding of what policy initiatives could potentially reduce these ‘avoidable’ ED visits to address the gaps in our healthcare system, such as increased access to mental health and dental care.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.